

Faecal immunochemical testing (FIT): Sources of result variation based on three years of routine testing of symptomatic patients in English primary care

Tim James¹, Brian D Nicholson², Rhiannon Marr¹, Maria Paddon¹, James E East³, Steve Justice¹, Jason L Oke², Brian Shine¹.

¹Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford University Hospitals Trust, Oxford, UK: Tim James, Head Biomedical Scientist ; Rhiannon Marr, Senior Biomedical Scientist; Maria Paddon, Senior Biomedical Scientist; Steve Justice, Chief Biomedical Scientist; Brian Shine, Consultant Chemical Pathologist

²Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK: Brian D Nicholson, NIHR Academic Clinical Lecturer & Macmillan GP Facilitator; Jason Oke, Senior Statistician

³Translational Gastroenterology Unit, and Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, University of Oxford, Oxford, UK: James E East, FRCP, Consultant Gastroenterologist

Brief Running Head: Result variation of Faecal Immunochemical Test (FIT)

Corresponding author: Prof Tim James, Tim.James@ouh.nhs.uk

Key words:

Faecal Immunochemical Test; Analytical variation; Preanalytical variation; Method performance.

Word counts:

Abstract: 237

Manuscript: 3096

Abstract

Introduction: We aimed to determine the analytical capabilities of a commonly used faecal immunochemical test (FIT) to detect faecal haemoglobin (Hb) in symptomatic people attending primary care in the context of the English NICE DG30 guidance.

Materials and Methods: Data obtained from independent verification studies and clinical testing of the HM-JACKarc FIT method in routine primary care practice were analysed to derive performance characteristics.

Results: Detection capabilities for the FIT method were 0.5 µg/g (limit of blank), 1.3 µg/g (limit of detection) and 3.0 µg/g (limit of quantitation). Of 33 non-homogenised specimens, 31 (93.9%) analysed in triplicate were consistently categorised relative to 10 µg/g, compared to all 33 (100%) homogenised specimens. Imprecision was higher (median 27.8%, (range 20.5% to 48.6%)) in non-homogenised specimens than in homogenised specimens (10.2%, (7.0 to 13.5%)). Considerable variation was observed in sequential clinical specimens from individual patients but no positive or negative trend in specimen degradation was observed over time ($p=0.26$).

Discussion: The FIT immunoassay evaluated is capable of detecting faecal Hb at concentrations well below the DG30 threshold of 10 µg/g and is suitable for application in this context. The greatest practical challenge to FIT performance is reproducible sampling, the pre-analytical step associated with most variability. Further research should focus on reducing sampling variability, particularly as post COVID-19 guidance recommends greater FIT utilisation.

Introduction

Colorectal cancer is globally the third most commonly occurring malignancy (1). Early disease is surgically treatable with good long-term outcomes (2). Most developed countries, including the UK, operate colorectal screening programmes using tests for the presence of haemoglobin. Screen detected cancers benefit from early diagnosis and treatment, and are associated with improved survival (2). The faecal immunochemical test (FIT) has largely replaced traditional guaiac based faecal occult blood tests for many reasons including increased analytical specificity (3).

To complement the NHS England Bowel Cancer Screening Programme (UKBCSP) (4), and the 2015 National Institute for Health and Care Excellence (NICE) NG12 Suspected Cancer guidelines (5), the 2017 DG30 NICE guidance (6) recommended the use of FIT for faecal haemoglobin (Hb) detection in patients presenting to primary care with low-risk abdominal symptoms suggestive of gastrointestinal cancer. The adoption of FIT in primary care was initially slow, with notable variation in uptake and implementation across England (7).

During the COVID-19 pandemic FIT has been rapidly implemented across the NHS to triage the highest risk symptomatic patients to a reduced colonoscopy resource (8,9).

The Oxford University Hospitals Trust (OUH) adopted FIT in 2016 in response to NG12 (5). This coincided with a desire from the clinical laboratory to move away from the poorly performing guaiac based method (10). Following a study by this group comparing the accuracy of the guaiac and FIT methods in symptomatic primary care patients, FIT was commissioned by Oxfordshire Clinical Commissioning Group (OCCG) as a direct access test for General Practitioners (11). Evaluation of the clinical performance of FIT between 2016 to 2019 in nearly 10,000 patients demonstrated the sensitivity for colorectal cancer to be 90.5%, specificity 91.3% with an associated negative predictive value of 99.9% (12).

Despite increasing uptake of FIT, there remains a clear need to understand FIT method characteristics (13). FIT testing, whether undertaken for screening asymptomatic or testing symptomatic populations, is dependent on the performance of the laboratory procedures used including both analytical and pre-analytical factors such as sampling (14). Whilst there has been significant work undertaken in the context of screening (15) there is less information available in the symptomatic population. This is an important omission as the characteristics of the screening population, and so the associated specimens, differ from symptomatic patients. For example, the age-range of the symptomatic population is broader and specimen characteristics, including faecal consistency, will differ in patients with changes in bowel habit. This may affect sampling, and sampling integrity.

In this study, we present our observations of FIT method performance since introducing it into routine clinical practice for a symptomatic primary care population. We include estimates of analytical performance, observations on longer term method precision, sampling reproducibility in homogenised compared to non-homogenised material, and consistency in sequential specimens from the same patients.

Material and methods

This study presents data from a single laboratory, within the Oxford University Hospitals NHS Foundation Trust (OUH) undertaking centralised analysis of FIT requests, mainly from primary care, for the 680,000 population of Oxfordshire. The assessment of FIT method performance was registered as a service evaluation on the OUH Datix register (CSS-BIO-3 4730).

FIT analysis was undertaken using the HM-JACKarc analyser (Hitachi Chemical Diagnostics Systems Co., Ltd, Tokyo, Japan and distributed in the UK by Alpha Labs Ltd, Eastleigh, Hants) which has an analytical range of 7 to 400 µg Hb/g faeces (manufacturers data).

All specimens were requested by NHS primary care clinicians and collected into standard faecal pots by patients, a sampling approach taken due to concerns about sampling capability when undertaken by (often elderly) symptomatic patients (11). Clinician advice from OUH and OCCG included guidance on delivering the sample to the laboratory on the same day as collection as Hb can degrade over time (16). Despite issuing guidance recommending that only a single specimen was required for FIT, many primary care clinicians continued to request more than one. This may have been due to clinicians being unaware of revised guidance as the standard practice for the guaiac method was to collect serial samples, the additional reassurance multiple specimens might provide, or because there remained doubt about test credibility (17,18).

On arrival in the laboratory the faecal specimens were sampled by laboratory staff using a sampling device, Extel Hemo-Auto MC (Alpha Labs Ltd, Eastleigh, Hants) designed for application with the HM-JACKarc. The whole sampling procedure was undertaken in a fume cupboard by staff with standard laboratory protective equipment and involved a 30 second vortex mix which for most specimens was adequate for release of the faecal pellet collected

into the dimples/grooves of the specimen collection device. All specimens were visually inspected to ensure complete suspension of specimen and if it was noted any residual specimen adherence mixing continued until all material was removed.

The FIT method limit of blank (LOB), limit of detection (LOD) and limit of quantitation (LOQ) were estimated using standard approaches (13, 19).

The LOB was calculated as the mean FIT result of the sample blank run as part of the method internal quality control (IQC) over 100 consecutive batches over 11 months and using three different reagent batches of specimen collection devices with no sample collected into the buffer.

The LOD was calculated using the $LOB + 1.645 (SD)$ of samples with “very low concentrations”, considered to be those giving FIT results above the manufacturers quoted LOB of $0.6 \mu\text{g/g}$. We used the average SD of 47 specimens analysed in duplicate between $0.5 \mu\text{g/g}$ and $1.0 \mu\text{g/g}$.

LOQ was estimated from an imprecision profile constructed from faecal samples analysed in duplicate across a wide FIT concentration range of naturally Hb positive material and was taken as the concentration at which the percent coefficient of variation (CV) was 10%. A 10% CV was selected as this has been recommended as an appropriate imprecision threshold for FIT method LOQ evaluation (13). The imprecision profile was constructed using data from 132 paired, within-batch replicates, analysed in seven different batches over a one-week period.

The on-instrument intermediate imprecision (*not* including sampling into the collection device) was estimated from two IQC materials provided by the manufacturer over several months to include the effects of different analysts, reagent and calibration material lot numbers. As the manufacturer’s two IQC materials both had concentrations above $10 \mu\text{g/g}$ (the threshold used to define a positive result in the NICE DG30 guidelines) we also explored

precision characteristics near to the LOD. This was prepared using a 1 in 40 dilution of the manufacturer's high IQC in sample device buffer.

It is unclear whether Hb is evenly distributed in faeces therefore we investigated the Hb concentration before and after sample homogenization. A total of 33 randomly selected faecal specimens arriving in standard faecal containers were sampled in triplicate, homogenized and then resampled a further three times. This resulted in six estimates for each faecal sample (3 non-homogenised replicates and 3 homogenised replicates). Imprecision of sampling was calculated as the CV, % for each set of three replicates. Individual faecal specimen replicates were sampled by the same member of staff but, overall, three different members of laboratory staff were involved in this part of the study. Homogenisation involved using a disposable wooden applicator stick (VWR International Ltd, Lutterworth, UK) to mix all faecal material within the stool container to a consistent

To verify the stability of Hb in the buffered collection device a selection of 13 specimens were analysed at three time points (at time zero, at 6 days and at 21 days) after storage at 4°C. Samples were selected to represent concentrations just below and above the 10µg/g decision threshold.

Sequential samples delivered to the lab on the same day allowed assessment of delayed analysis on Hb concentration. These sequential specimens represented maximum within patient error as Hb concentrations reflected total variability (between day biological variation, analyte instability, sampling error and immunoassay method imprecision).

Differences between the imprecision of sampling between non-homogenised and homogenised sampling were assessed using a Wilcoxon rank test with continuity correction, the null hypothesis being that the distribution of $x - y$ (CV, % in homogenised group – CV, % in non-homogenised group) is symmetric about 0.

For patients with multiple specimens and discordant results (at least one result greater than, and at least one result less than 10 µg/g), we examined whether there was an association between the likelihood of a positive result and delay in processing the specimen in the laboratory of 48 or 72 hours. In this group, we also examined whether there was an association between a positive result and the sequence number of the specimen. Both were assessed using the Chi-squared test.

Results

The distribution of blank results was non-gaussian and was therefore calculated with two non-parametric approaches. The 95th centile the LOB was 0.5 µg/g (95% CI, 0.4-0.6) and through log transformation of the blank data (zero replaced by 0.1) which also derived a LOB of 0.5 µg/g. The LOD was determined as 1.3 µg/g and LOQ was 3 µg/g.

Method reproducibility for the low IQC material (table 1) across four different lot numbers with mean concentrations between 24 and 27 µg/g was between 6.4% to 8.8 CV,%.

Comparatively, the high IQC, at concentrations between 90 and 100 µg/g ranged from 4.4% to 6.8%. Imprecision characteristics of a highly diluted IQC material, targeted to give a concentration near the LOD were mean 1.5 µg/g, SD 0.5 µg/g, CV, % 33.9 %.

Of 33 non-homogenised samples, 31 (93.9%) were consistent with respect to their categorisation above or below the 10 µg/g threshold (figure 1).

The mean result was below 10 µg/g (negative) in 27 (82%) and six (18%) had mean results above (positive).

Four of the six positive results had all three replicates above the threshold and imprecision estimates were calculated: median CV, % of 27.8%, range 20.5% to 48.6%. Two further samples had discrepant result relative to the 10 µg/g NICE threshold. The first had replicates

of <1.1, <1.1, 34.5 µg/g (two below the LOD and one above the LOQ). Clinical details of this patient were rectal bleeding and endoscopy showed an 8 mm polyp in the sigmoid. Histology revealed the polyp to be non-dysplastic and hyper-plastic. This patient was discharged. The second of these discrepant results had replicates <1.1, <1.1, 14.7 µg/g (two below the LOD and one positive relative to the NICE threshold of 10 µg/g). This patient was being followed up by an established vague symptoms pathway (20) and whilst nothing abnormal was detected after 9 months of follow-up, at the time of patient assessment they were noted to be taking non-steroidal anti-inflammatory drugs.

In the homogenised specimen group, all 33 (100%) specimens were consistently above or below the 10 µg/g threshold (figure 1). Of the 33 groups, 28 had a mean result below 10 µg/g (negative) and 5 had mean results above (positive). Categorisation as positive or negative was consistent in all replicates relative to a threshold of 10 µg/g. Four of the five positive specimens in the homogenised set had imprecision estimates calculated: median CV, % of 10.2%, range 7.0 to 13.5%. This was lower than, but not statistically significant from ($p = 0.10$), the imprecision observed in the non-homogenised samples. The fifth positive result had values above the limit of linearity which precluded calculation of imprecision.

Thirteen specimens selected as their initial result was above the LOQ, (5 below the 10µg/g threshold and 8 above) were repeat tested. Mean concentration, day 1 was 15.1 µg/g (range 3.1 to 30.9); storage for 6 days showed no significant change ($p=0.24$), mean 17.1 µg/g (2.3 to 41.6) and neither did storage for 21 days ($p=0.79$), mean 14.6 (range 2.3 to 32.3). All 13 specimens had consistent categorisation (positive/negative) when repeat tested at 6 days however at 21 days one specimen would have been re-categorised as negative as it had fallen from 25 to 6 µg/g.

More than one sample was sent within a 3-month period by 524 patients: 302 returned two specimens; 222 returned three; two returned four; and one returned five. Of the 225 patients

with three or more specimens: 197 (87.6%) had concordant results for all specimens (188 negative, 9 positive). 28 (12.4%) had discordant results, that is, at least one value more, and at least one value less, than 10 µg/g. There was no obvious trend on visual review of plots of individual patient's FIT values over time and no association between the likelihood of a positive result based on a delay of more than 2 days in the specimen reaching the laboratory ($p = 0.84$, Chi-squared test). There was no association between the likelihood of a positive result and the number in the sequence of a particular patient's specimens ($p = 0.21$, Chi-squared test). Figure 2 shows the serial FIT concentrations in the 28 patients whose serial results were inconsistently categorised relative to the 10 µg/g threshold.

Discussion

In this study the LOB (0.5 µg/g), LOD (1.3 µg/g) and LOQ (3.0 µg/g) for the HM-JACKarc FIT method were lower than the current NICE threshold of 10 µg/g and we conclude this method is suitable for application in this context. The detection capabilities are also marginally better than the manufacturers claims of LOB 0.6 µg/g, LOD 2.0 µg/g, LOQ 7.0 µg/g. This may have future relevance as a recent large study examining the use of FIT in the two week wait cancer pathway proposed using the manufacturer reported LOD of the HM-JARKarc at 2.0 µg/g as the cut off for referral for to secondary care. [21]

Method imprecision was consistently <9% and although the concentration of Hb present in the two IQC materials (25 µg/g and 95 µg/g) are satisfactory for method control at positive concentrations this approach does not provide adequate confidence <10 µg/g, where most clinical results are observed. We suggest an additional IQC material between 5 and 10 µg/g is introduced.

Imprecision rises when faecal sampling is taken into consideration. Imprecision in homogenised specimens (median 10.2%, upper estimate 13.5%) was lower than non-homogenised specimens (median 27.8%, 48.6%). Importantly two samples in the non-homogenised group were inconsistently classified relative to the 10 µg/g threshold. This would suggest that Hb is not uniformly distributed in the faecal specimen, a finding consistent with other faecal constituents (22).

The manufacturer recommends stabilisation of Hb within collection devices used by the patient using non-homogenised material, a process that in a small number of cases may cause false negative or false positive results. However, the possibility that home sampling may miss pockets of faecal Hb must be balanced against the risk that Hb degrades over time if faecal samples are not stabilised in buffer (16). The stability of Hb in the sampling device buffer appeared reasonable for most specimens up to 21 days although one specimen showed

notable deterioration from above to below the 10 µg/g threshold. A weekly FIT batch analysis would minimise the potential of this degradation to misclassify results, however daily analysis would provide more appropriate turnaround times for 2-week wait testing. Our serial sample data provides insight into sample variability and stability when a standard collection pot without buffer is used. We found no association between the likelihood of a positive or negative result based on a delay >2 days in the specimen reaching the laboratory in serial samples from individual patients. Time intervals between specimens were variable and the magnitude of degradation in individual specimens remains unknown. However, it is possible that the variability between days (a component of biological variability) and from sampling (a component of analytical variability) may be larger than the changes in concentration associated with degradation. If degradation were the dominant variable the results of the time series analysis would be significant.

In a previous diagnostic accuracy study of one vs two specimens it was concluded that two offered no advantage over one (23) despite sequential results in some individuals being 400 µg/g and then <10 µg/g. Another study of two specimen strategies for colorectal cancer in a symptomatic population noted 39.2% non-concordance between the first and the maximum FIT result (24). More recently FIT testing in a symptomatic population in a 2 week wait pathway found 12.5% of colorectal cancers were missed using a single, patient collected, specimen (25). The method utilised the OC-SensorTM with a reported detection limit of 4 µg/g and also reported the majority of FIT results from patients with colorectal cancer had very high values (>150 µg/g). It is not certain what the relative contribution of biological variation, inconsistent bleeding or sampling imprecision have on FIT results but these and other studies (7) show whatever strategy is used a small number of false negatives occur. Collection of samples from patients with a change in bowel habit presents specific additional challenges since faecal water content can vary between 60 and 82% (26). This dilutional

effect will impact on quantitative measures and the lack of form may affect entrapment of the specimen within the manufacturer's collection device. Furthermore, concern about faecal-oral or aerosol transmission of COVID-19 (27) during sample manipulation and the need for a period of very high throughput need to be balanced against analytic accuracy.

In the last year both the NICE FIT steering group and our own centre have reported diagnostic accuracy estimates in large symptomatic populations. The NICE FIT group reported an area under the receiver operating characteristic curve (AUC) of 0.93 (95% CI 0.92 to 0.95) in a multicentre setting utilising specimens taken into collection devices by the patient in 9822 individuals (21). Comparatively at our single centre in 9896 patients, where sampling was undertaken by laboratory staff, the AUC was 0.94 (0.91 to 0.97) (12). This would suggest that whilst sampling strategies are important the impact on outcome of each approach are similar.

In summary we have found that a commonly used FIT method shows good consistency of categorising Hb results against the DG30 threshold of 10 µg/g, and therefore appears suitable for this clinical application. However, there appear numerous sources of variability that require further investigation and optimisation and the International Federation of Clinical Chemistry have set up a working group to address these issues (28). Further studies should investigate the relative contributions of biological variation, sampling technique, Hb stability and method performance in relation to false negative results. It would be particularly valuable to accurately assess the mass of faeces collected into collection devices when sampling is undertaken by patients, rather than laboratory staff, as this is the setting in which most specimens will be collected. Sources of variation become even more important as FIT is now recommended to reprioritise patients with lower GI cancer symptoms whose tests have been delayed by the COVID-19 pandemic.

Summary sentence

This work represents an advance in biomedical science as it provides independent FIT method verification data in a symptomatic primary care setting and identifies sources of variation of importance to colorectal cancer detection.

Acknowledgements

James E. East was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. Brian D Nicholson is an NIHR Academic Clinical Lecturer and is supported by the NIHR Oxford Medtech and In-Vitro Diagnostics Co-operative. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR or the Department of Health.

Disclosure statement

None of the authors have any relevant financial or non-financial competing interests to declare.

Summary Table

What is known about this subject:

- Faecal immunochemical testing (FIT) is increasingly used to detect haemoglobin (Hb) at low concentrations in specimens from symptomatic primary care patients.
- Several methods are available for FIT but there are limited extended method evaluations in this context against the NICE recommended threshold of 10 µg/g.

What this paper adds:

- The FIT method assessed demonstrated good analytical performance characteristics against the requirements of NICE DG30.
- Sampling technique is subject to high imprecision and appears to be higher in non-homogenised faecal specimens
- Biological variability also appears to contribute to result outcome

References

1. World Health Organization. Colorectal cancer Source: Globocan 2018 Number of new cases in 2018, both sexes, all ages [Internet]. 2018. [cited 30 May 2019]. Available: http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf
2. Wilkins T, McMechan D, Talukder A. Colorectal Cancer Screening and Prevention. *Am Fam Physician*. 2018;97:658-665.
3. Allison JE, Fraser CG, Halloran SP, Young GP. Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). *Gut Liver* 2014;8:117–30
4. <https://www.nhs.uk/conditions/bowel-cancer-screening/> (Accessed 28 December 2020).
5. National Institute for Health and Care Excellence. Suspected cancer: Recognition and referral. NICE guideline (NG12, 2017. [updated 11 September 2020] <https://www.nice.org.uk/guidance/ng12>. (Accessed 28 December 2020).
6. National Institute for Health and Care Excellence. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care. Diagnostics guidance (DG30). 2017. <https://www.nice.org.uk/guidance/dg30> (Accessed 28 December 2020).
7. Mole G, Withington J, Logan R. From FOBt to FIT: making it work for patients and populations. *Clinical Medicine* 2019; 19: 196–9

8. <https://www.nice.org.uk/Media/Default/About/COVID-19/Specialty-guides/triaging-patients-with-lower-gi-symptoms.pdf> (Accessed 28 December 2020).
9. Rees CJ, East JE, Oppong K, Veitch A, McAlindon M, Anderson J, Hayee B, Edwards C, McKinlay A, Penman I. Restarting gastrointestinal endoscopy in the deceleration and early recovery phases of COVID-19 pandemic: Guidance from the British Society of Gastroenterology. *Clin Med (Lond)*. 2020;20:352-358.
10. Fraser CG. Faecal occult blood tests- eliminate, enhance or update? *Ann Clin Biochem* 2008;45:117–21
11. Nicholson BD, James T, East JE *et al*. Experience of adopting faecal immunochemical testing to meet the NICE colorectal cancer referral criteria for low-risk symptomatic primary care patients in Oxfordshire, UK. *Frontline Gastroenterol* 2018; 10:347-355.
12. Nicholson BD, James T, Paddon M, Justice S, Oke JL, East JE , Shine B. Faecal immunochemical testing for adults with symptoms of colorectal cancer attending English primary care: a retrospective cohort study of 14 487 consecutive test requests. *Aliment Pharmacol Ther*. 2020; 52:1031-1041.
13. Fraser CG, Benton SC. Detection capability of quantitative faecal immunochemical tests for haemoglobin (FIT) and reporting of low faecal haemoglobin concentrations. *Clin Chem Lab Med*. 2019;57:611-616.

14. Godber IM, Benton SC, Fraser CG. Setting up a service for a faecal immunochemical test for haemoglobin (FIT): a review of considerations, challenges and constraints. *J Clin Pathol*. 2018;71:1041-1045.
15. Carroll MRR, Piggott C, Pearson S, et al. *Evaluation of quantitative faecal immunochemical tests for haemoglobin*. Guildford, UK: Guildford Medical Device Evaluation Centre (GMEC), 2013.
16. Brown LF, Fraser CG. Effect of delay in sampling on haemoglobin determined by faecal immunochemical tests. *Ann Clin Biochem*. 2008;45:604-5.
17. Steele R, Forgacs I, McCreanor G, Benton S, Machesney M, Rees C, et al. Use of faecal occult blood tests in symptomatic patients. *BMJ*. 2015;351
18. Hamilton W, Hajioff S, Graham J, Schmidt-Hansen M. Authors' reply to Steele and colleagues. *BMJ* 2015;351.
19. Linnet K, Kondratovich M. Partly nonparametric approach for determining the limit of detection. *Clin Chem*. 2004;50:732-40.
20. Nicholson BD, Oke J, Friedemann Smith C, Phillips JA, Lee J, Abel L, Kelly S, Gould I, Mackay T, Kaveney Z, Anthony S, Hayles S, Lasserson D, Gleeson F. The Suspected CANcer (SCAN) pathway: protocol for evaluating a new standard of care for patients with non-specific symptoms of cancer. *BMJ Open*. 2018;8:e018168.

21. D'Souza N, Delisle T, Chen M, Benton S, Abulafi M, NICE FIT Steering Group. Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study. *Gut*. 2020 Oct 21;gutjnl-2020-321956. doi: 10.1136/gutjnl-2020-321956.
22. Gratton J, Phetcharaburanin J, Mullish BH, Williams HR, Thursz M, Nicholson JK, Holmes E, Marchesi JR, Li JV. Optimized Sample Handling Strategy for Metabolic Profiling of Human Feces. *Anal Chem*. 2016; 88: 4661-8.
23. Turvill J, Mellen S, Jeffery L, Bevan S, Keding A, Turnock D. Diagnostic accuracy of one or two faecal haemoglobin and calprotectin measurements in patients with suspected colorectal cancer. *Scand J Gastroenterol*. 2018;53:1526-1534.
24. Auge JM, Fraser CG, Rodriguez C, Roset A, Lopez-Ceron M, Grau J, Castells A, Jimenez W. Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients. *Clin Chem Lab Med*. 2016; 54:125-32.
25. Chapman C, Bunce J, Oliver S, Ng O, Tangri A, Rogers R, Logan RF, Humes DJ, Banerjee A. Service evaluation of faecal immunochemical testing and anaemia for risk stratification in the 2-week-wait pathway for colorectal cancer. *BJS Open*. 2019;3:395-402.
26. Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. *Aliment Pharmacol Ther*. 2016; 44:693-703.

27. Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, Ng YY, Chu MY, Chung TWH, Tam AR, Yip CCY, Leung KH, Fung AY, Zhang RR, Lin Y, Cheng HM, Zhang AJX, To KKW, Chan KH, Yuen KY, Leung WK. [Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis](#). *Gastroenterology*. 2020;159:81-95.

28. Benton SC, Symonds E, Djedovic N, Jones S, Deprez L, Kocna P, Auge JM, International Federation of Clinical Chemistry Faecal Immunochemical Test Working Group (IFCC FIT-WG). Faecal Immunochemical Tests for Haemoglobin: Analytical Challenges and Potential Solutions. *Clin Chim Acta*. 2021 Feb 8;S0009-8981(21)00040-1. doi: 10.1016/j.cca.2021.01.024. Online ahead of print.

Table 1: Imprecision estimates over a 12 month period

QC Lot number	Period (n)	Low QC			High QC		
		Mean (µg/g)	SD (µg/g)	CV, %	Mean (µg/g)	SD (µg/g)	CV, %
168AHG	7 weeks (57)	24.7	1.6	6.4	90.0	4.0	4.4
169AHJ	36 weeks (259)	27.2	2.4	8.8	91.4	4.3	4.7
170AIA	5 weeks (32)	25.9	2.0	7.7	97.7	6.7	6.8
171AIE	13 weeks (117)	26.2	2.0	7.6	97.9	6.7	6.8

Figure 1 legend: Specimen preparation effects. 33 specimens analysed in triplicate prior to and after homogenisation. Results show the observed concentration range (lowest to highest) with each specimen presented sequentially with homogenised (circles) and non-homogenised (triangles) results adjacent.




Figure 2 legend: Variability of sequential results the 28 patients whose specimens had discordant categorisation relative to a 10 $\mu\text{g/g}$ threshold. Each panel represents a single patient, time (hours) vs concentration ($\mu\text{g/g}$) profile showing the inconsistent patterns observed: round points represent those results categorised as negative and triangle points positive. The horizontal line on each panel is the 10 $\mu\text{g/g}$ threshold defining a positive or negative result.

